Skip to main
COCH

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical is a hearing health company focused on providing medical technologies across the hearing loss spectrum. They have developed the Esteem FI-AMEI, a fully implanted active middle ear implant that utilizes the ear's natural anatomy, and are currently conducting a pivotal trial of their Acclaim CI, a first-of-its-kind fully implanted cochlear implant. This device has the potential to disrupt the current market, as it addresses the underutilization of cochlear implants by offering a discreet, fully implanted option. The company's strong financial position, potential for high market adoption, and unique technology make it an attractive investment opportunity.

Bears say

Envoy Medical is facing several hurdles that could limit their success in the hearing health market. Despite having a promising product in Esteem FI-AMEI, their success is reliant on a single reportable segment, with the Acclaim CI still an investigational device and at risk of failure in clinical trials. Additionally, the company's financials show a negative cash flow and a history of operating losses, along with a high discount rate of 20% used in the DCF analysis, indicating a higher risk associated with investing in this company.

COCH has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 2 analysts, COCH has a Strong Buy consensus rating as of Aug 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.